Clinical Trial Update: A Study of BBI503 in Asymptomatic Recurrent Ovarian Cancer Patients With CA-125 Elevation [Phase 2]

View source ↗

Summary

Phase 2 trial of BBI503 in asymptomatic recurrent ovarian cancer with CA-125 elevation was terminated; results posted in 2022.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Ovarian Cancer

Drugs mentioned

• BBI503

Snippet

Sponsor: Sumitomo Pharma America, Inc. | Conditions: Cancer, Ovarian Cancer | Phase 2 | Status: TERMINATED | Results posted: 2022-08-29